Radiobiology & Cancer

Summary

The Radiobiology and Cancer group, led by Ferran Guedea, works on the translational aspect of integrating radiobiological findings into clinical patient outcome parameters and clinical studies

514 Publications

Strategic lines

Study on:
1. How high doses of radiotherapy (SBRT, IORT and HDR) could trigger immune stimulation through modulation of cytokines and immune cells in plasma.
2. Predictive radiation sensitivity tests.
3. New therapeutic strategies in brachytherapy.
4. New therapeutic strategies in external radiotherapy.
5. Evaluation of quality of life in the treatment of prostate cancer.
6. Application of intracranial stereotactic radiotherapy (SRT) and
7. Stereotactic body radiotherapy (SBRT) techniques.

Selected Publications

- Garin O, Suarez JF, Guedea F, Pont A, Pardo Y, Goni A, Marino A, Hervas A, Herruzo I, Cabrera P, Sancho G, de Leon JP, Macias V, Gutierrez C, Castells M, Ferrer M, Multicentric Spanish Clinicall GRP. Comparative Effectiveness Research in Localized Prostate Cancer: A 10-Year Follow-up Cohort Study. Int J Radiat Oncol Biol Phys. 2021;110(3):718-726. doi:10.1016/j.ijrobp.2020.12.032. IF:7,04.

- Hannoun Levi JM, Gal J, Van Limbergen E, Chand ME, Schiappa R, Smanyko V, Kauer Domer D, Pasquier D, Lemanski C, Racadot S, Houvenaeghel G, Guix B, Belliere Calandry A, Loessl K, Polat B, Gutierrez C, Galalae R, Polgar C, Strnad V. Salvage Mastectomy Versus Second Conservative Treatment for Second Ipsilateral Breast Tumor Event: A Propensity Score-Matched Cohort Analysis of the GEC-ESTRO Breast Cancer Working Group Database. Int J Radiat Oncol Biol Phys. 2021;110(2):452-461. doi:10.1016/j.ijrobp.2020.12.029. IF:7,04.

- Alcibar OL, Nadal E, Palomar IR, Navarro Martin A. Systematic review of stereotactic body radiotherapy in stage III non-small cell lung cancer. Transl Lung Cancer Res. 2021;10(1):529-538. doi:10.21037/tlcr-2020-nsclc-04. IF:6,50.

- Linares Galiana I, Berenguer Frances MA, Canas Cortes R, Pujol Canadell M, Comas Anton S, Martinez E, Laplana M, Perez Montero H, Pla Farnos MJ, Navarro Martin A, Nunez M, Both B, Guedea F. Changes in peripheral immune cells after intraoperative radiation therapy in low-risk breast cancer. J Radiat Res. 2021;62(1):110-118. doi:10.1093/jrr/rraa083. IF:2,72.

- Laplana M, Cozzi S, Najjari D, Martin MI, Rodriguez G, Slocker A, Sancho I, Pla MJ, Garcia M, Gracia R, Pera J, Guedea F, Gutierrez C. Five-year results of accelerated partial breast irradiation: A single-institution retrospective review of 289 cases. Brachytherapy. 2021;20(4):807-817. doi:10.1016/j.brachy.2021.02.003. IF:2,36.

Selected Projects

- 18NOF013. Grup d'Investigació en Radiobiologia i Càncer. (2017SGR1088). DIR.GEN.SALUT PUBLICA, DEP.SALUT GE. 2018-2021. IP:GUEDEA I EDO,FERRAN.

- ACL:17ACL058. PREVALENCIA Y CARACTERIZACIÓN DEL DOLOR IRRUPTIVO EN PACIENTES ONCOLÓGICOS EN TRATAMIENTO CON RT 3D PÉLVICA CON PROCTALGIA. 2017-2026. IP:SUSANA MARIN BORRAS.

- ACL:16ACL044. ESTUDIO DE FASE 3 ALEATORIZADO, DOBLE CIEGO Y CONTROLADO CON PLACEBO DE JNJ-56021927 EN SUJETOS CON CÁNCER DE PRÓSTATA LOCALIZADO O LOCALMENTE AVANZADO Y DE ALTO RIESGO QUE ESTÁN RECIBIENDO TRATAMIENTO CON RADIOTERAPIA PRIMARIA. (56021927PCR3003). JANSSEN CILAG S.A. 2016IP:ANNA MARIA BOLADERAS INGLADA.

- ACL:16ACL025. INTRABEAM: PRECISION HYPOFRACTIONATED RADIOTHERAPY WITH A SYSTEMIC IMMUNE RESPONSE. 2016IP:FERRAN GUEDEA I EDO.

- ACL:15ACL171. IMMUNE MODULATION BY BRACHYTHERAPY IN BLOOD AND TUMOR MICROINVIRONMENT. FUNDACIO IDIBELL. 2015IP:FERRAN GUEDEA I EDO.

More Information

We currently have three industry-funded projects under way:

Immune modulation through brachytherapy in blood and tumour microenvironment.
Detection of systemic immune response to peripheral blood provided by high doses of radiation given to the lung in stereotactic conditions.
INTRABEAM: precision hypofractionated radiotherapy with immune-system response.
Over the past five years, we have obtained two competitive projects, Healthcare Research and Development Strategy grants:
Long-term effectiveness: 10-year follow-up of the “Spanish Multicentre Study of Localised Prostate Cancer” cohort (PI13 / 00412).
Efficacy of new treatments for low-risk localised prostate cancer: a randomised clinical trial (PI13 / 00412).